WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Â Proceeds will be used...
1k Views
Broker, Sector and Retail Analytics of 2016 HK IPOs
Since we published our first annual HK IPO analytics (5 Key Charts to Wrap-Up 2015 HK IPO - Broker, Sector, and Retail Analytics) in Feb 2015, it...
570 Views
Smartkarma - ECM Coverage Weekly Update (21 Nov 2016)
Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs.Accuracy Rate:Our accuracy...
331 Views
Smartkarma - ECM Coverage Weekly Update (14 Nov 2016)
Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs.Accuracy Rate:Our accuracy...
357 Views
Smartkarma - ECM Coverage Weekly Update (7 Nov 2016)
Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs.Accuracy Rate:Our accuracy...
386 Views